Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aadi Bioscience (AADI) has provided an update.
Loretta Itri, M.D., is stepping down as Chief Medical Officer but will receive a generous severance package and maintain a consulting role with her former company. Neil Desai, Ph.D., also plans to leave his role as Executive Chairman, with a severance in line with his agreement. Both will continue their involvement with the company, Itri through consulting and Desai as a board member, allowing them to retain their equity awards. This move could signal strategic shifts or a refresh in leadership, offering potential impacts on the company’s direction and stock performance.
For a thorough assessment of AADI stock, go to TipRanks’ Stock Analysis page.